These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37160267)

  • 1. Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis.
    Rudolph D; Redinger N; Schwarz K; Li F; Hädrich G; Cohrs M; Dailey LA; Schaible UE; Feldmann C
    ACS Nano; 2023 May; 17(10):9478-9486. PubMed ID: 37160267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis.
    Yao R; Wang B; Fu L; Li L; You K; Li YG; Lu Y
    Microbiol Spectr; 2022 Feb; 10(1):e0247721. PubMed ID: 35170994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.
    Eckhardt E; Li Y; Mamerow S; Schinköthe J; Sehl-Ewert J; Dreisbach J; Corleis B; Dorhoi A; Teifke J; Menge C; Kloss F; Bastian M
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0143822. PubMed ID: 36975792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
    Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the pharmacodynamic activity of combinations with the new anti-tuberculosis drug pyrifazimine
    Liu HT; Fu L; Wang B; Wang N; Li DS; Ding YM; Yao R; Qi XT; Lu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jun; 45(6):560-566. PubMed ID: 35658380
    [No Abstract]   [Full Text] [Related]  

  • 12. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Regimens Containing TBI-166, a New Drug Candidate against
    Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
    Ramey ME; Kaya F; Bauman AA; Massoudi LM; Sarathy JP; Zimmerman MD; Scott DWL; Job AM; Miller-Dawson JA; Podell BK; Lyons MA; Dartois V; Lenaerts AJ; Robertson GT
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0059723. PubMed ID: 37791784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline: Current status and future perspectives.
    Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
    J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.
    Xu J; Li D; Shi J; Wang B; Ge F; Guo Z; Mu X; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0153222. PubMed ID: 37255473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.